291
Views
65
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

, , , , , , , , , , , , & show all
Pages 462-469 | Received 23 Aug 2007, Accepted 13 Nov 2007, Published online: 01 Jul 2009

References

  • DeVita V T, Jr, Canellos G P, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1: 248–250
  • Schein P S, DeVita V T, Jr, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisolone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–422
  • Fisher R I, DeVita V T, Jr, Johnson B L, et al. Prognostic factors in advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977; 63: 177–182
  • Gayner E R, Ultmann J E, Golomb H M, et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, Oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol 1985; 3: 1596–1604
  • Coltman C A, Dahlberg S, Jones S E, . Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. Cancer Chemotherapy: Challenges for the Future, K Kimura, et al. Excerpta Medica, Tokyo 1988; 194–202
  • Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
  • Shipp M A. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high-risk” disease?. Blood 1994; 83: 1165
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346: 235–242
  • Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
  • Sehn L H, Berry B, Chhanabhai M, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
  • Jaffe E. Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001, World Health Organization Classification of Tumours
  • Altman G D. Practical Statistics for Medical Research. Chapman and Hall, London 1991
  • Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387–6393

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.